Elke Wynberg

Evolution of COVID-19 symptoms during the first 12 months after illness onset 4 105 Total Mild Moderate Severe Critical p-value N=342 N=99 N=145 N=56 N=42 Physical measurements ¶ Maximum HR, beats/min 82 (72-94) 74 (66-81) 83 (74-92) 95 (84-107) 94 (80-110) <0.001 Maximum RR, breaths/min 20 (16-24) 16 (16-16) 20 (19-24) 25 (20-32) 26 (20-33) <0.001 Minimum SpO2, % 96 (91-98) 98 (97-99) 96 (93-98) 88 (85-89) 85 (78-90) <0.001 SARS-CoV-2 serology at enrolment ‡ 5 (0-17) 0 (0-3) 8 (0-18) 15 (7-20) 16 (12-19) <0.001 Ct-value at enrolment (PCR) Nasopharyngeal 26 (19-33) 25 (19-31) 26 (16-33) 30 (27-32) 27 (22-33) 0.55 Throat 28 (0-32) 28 (22-32) 28 (0-32) 12 (0-31) 34 (32-36) 0.17 Died during follow-up 2 0 1 1 0 - Vaccinated during follow-up 205 (60%) 64 (65%) 88 (61%) 24 (43%) 29 (69%) - Time from illness onset to vaccination, days 249 (152-365) 187 (113-300) 253 (168-320) 285 (77-399) 384 (358-393) <0.001 Study characteristics Place of recruitment - Non-hospital 161 (47%) 85 (86%) 72 (50%) 4 (7%) 0 (0%) Hospital 181 (53%) 14 (14%) 73 (50%) 52 (93%) 42 (100%) Type of inclusion <0.001 Prospective 250 (73%) 86 (87%) 114 (79%) 39 (70%) 11 (26%) Retrospective 92 (27%) 13 (13%) 31 (21%) 17 (30%) 31 (74%) Time from illness onset to enrolment in study, days 12 (6-41) 7 (4-12) 12 (6-32) 18 (11-72) 74 (20-93) <0.001 Prospective inclusions only 9 (5-14) 6 (4-9) 9 (6-16) 13 (11-17) 17 (11-20) <0.001 Retrospective inclusions only 85 (72-94) 92 (66-94) 85 (76-92) 82 (72-99) 88 (72-96) 0.91 Follow-up time (from enrolment in study), days 217.5 (126.0-343.0) 204.0 (147.0-336.0) 223.0 (127.0-342.0) 171.5 (56.0-348.5) 335.5 (110.0-349.0) 0.073 Prospective inclusions only 190.0 (91.0-281.0) 196.5 (146.0-286.0) 216.5 (126.0-307.0) 84.0 (41.0-176.0) 85.0 (54.0-168.0) <0.001 Retrospective inclusions only 349.0 (336.0-356.0) 364.0 (341.0-379.0) 350.0 (272.0-357.0) 354.0 (349.0-356.0) 342.0 (333.0-350.0) 0.074 Lost to follow-up 66 22 26 13 5 -

RkJQdWJsaXNoZXIy MTk4NDMw